Engineers Gate Manager LP Raises Stake in Boston Scientific Corporation $BSX

Engineers Gate Manager LP lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 26.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 706,897 shares of the medical equipment provider’s stock after acquiring an additional 148,852 shares during the period. Boston Scientific accounts for approximately 0.8% of Engineers Gate Manager LP’s investment portfolio, making the stock its 13th biggest holding. Engineers Gate Manager LP’s holdings in Boston Scientific were worth $67,403,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in BSX. Norges Bank acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $2,199,395,000. Egerton Capital UK LLP raised its position in shares of Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Maverick Capital Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $280,735,000. Farallon Capital Management LLC raised its position in shares of Boston Scientific by 56.7% during the 4th quarter. Farallon Capital Management LLC now owns 7,439,564 shares of the medical equipment provider’s stock worth $709,362,000 after acquiring an additional 2,693,007 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in shares of Boston Scientific by 31.9% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 11,035,628 shares of the medical equipment provider’s stock worth $1,052,247,000 after acquiring an additional 2,668,230 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BSX. UBS Group cut their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Barclays dropped their price objective on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a report on Thursday, May 28th. Raymond James Financial reaffirmed an “outperform” rating and set a $88.00 price objective (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. The Goldman Sachs Group set a $71.00 price objective on Boston Scientific in a report on Thursday, May 28th. Finally, Citigroup dropped their price objective on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $85.08.

Boston Scientific Stock Down 4.4%

Shares of NYSE:BSX opened at $44.86 on Thursday. The stock has a market cap of $66.68 billion, a P/E ratio of 18.77, a P/E/G ratio of 0.90 and a beta of 0.56. The firm has a fifty day moving average price of $55.38 and a 200 day moving average price of $73.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific Corporation has a 1-year low of $44.79 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.36 EPS for the current year.

Boston Scientific declared that its board has initiated a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to reacquire up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, Director David C. Habiger purchased 2,250 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock worth $554,012 over the last ninety days. 0.34% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.